SLS News and Press, SELLAS Life Sciences Group Inc. From 12/13/23

NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...

VANCOUVER, British Columbia, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Solaris Resources Inc . (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to announce that Solaris and OMF Fund IV SPV D LLC and OMF Fund IV SPV E LLC, entities managed by Orion Mine Fina...

- Independent Data Monitoring Committee (IDMC) Recommended Continuation of Phase 3 REGAL Trial Without Any Modifications - - IDMC Expressed Satisfaction with Speed of Enrollment and High Study Integrity - - IDMC Will Review Most Current Survival Data at Next Scheduled IDMC Mee...

NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...

– FDA feedback indicates Company’s CMC plans are in alignment with FDA’s requirements and expectations towards a BLA – – CMC regulatory alignment is critical step in approval pathway for GPS – NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) ...

SELLAS Life Sciences Group Inc. (SLS) is expected to report for Q3 2023

2023-11-09 17:28:54 ET More on SELLAS Life Sciences SELLAS Life Sciences announces $4M registered direct offering priced at-the-market under Nasdaq rules Sellas Life Sciences stock jumps on FDA fast track designation for PTCL treatment Seeking Alpha’s Quant Ra...

-Phase 3 REGAL Trial of Galinpepimut-S (GPS) on Track to Complete Enrollment ex-China in November 2023 - - Positive Initial Topline Phase 2a Data of SLS009 Reported with First Complete Response Achieved in Acute Myeloid Leukemia (AML) Patient Resistant to Venetoclax Combination Therapie...

Median overall survival for GPS and Keytruda ® combination was 18.4 Months compared to 13.8 Months in a Keytruda ® single agent study (KEYNOTE-028) and 11-14 Months with standard of care chemotherapy Combination of GPS and Keytruda ® ...

2023-10-31 08:53:38 ET More on SELLAS Life Sciences Sellas Life Sciences stock jumps on FDA fast track designation for PTCL treatment SELLAS gains on FDA orphan drug status for its SLS009 Seeking Alpha’s Quant Rating on SELLAS Life Sciences Historical ...